Stay updated on Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical trial record for pembrolizumab plus GM-CSF in biliary cancer is now displayed, with details on the completed study, its eligibility criteria, treatment plan, and measured outcomes.SummaryDifference54%

- Check16 days agoChange DetectedThe displayed ClinicalTrials.gov revision changed from v3.7.2 to v3.8.0, while the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434, with a link to updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 while the 403 error page remains otherwise unchanged.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision number changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error with the site header and footer visible, replacing the prior study record content.SummaryDifference19%

Stay in the know with updates to Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & GM-CSF in Biliary Cancer Clinical Trial page.